|
FY2021
12 months to Dec 31, 2021
|
FY2020
12 months to Dec 31, 2020
|
FY2019
12 months to Dec 31, 2019
|
|
|---|---|---|---|
| Operating activities | |||
| Net income | |||
| Depletion and amortization | |||
| Royalty interest impairment (Note 5b) | |||
| Non-cash cost of sales related to prepaid gold interest (Note 6) | |||
| Change in fair value of prepaid gold interest (Note 6) | |||
| Income tax expense | |||
| Share-based compensation | |||
| Finance expense | |||
| Foreign exchange loss (gain) | |||
| Unrealized loss (gain) on warrants | |||
| Withholding and income taxes paid | |||
| Gain on amendment of royalty interest (Note 4) | |||
| Gain on royalty transactions (Note 4) | |||
| Gain on conversion of debenture (Note 4) | |||
| Changes in non-cash working capital (Note 12) | |||
| Net cash provided by operating activities | |||
| Investing activities | |||
| Acquisition of royalty, stream and other interests (Note 4 and 5) | |||
| Acquisition of prepaid gold interest (Note 6) | |||
| Proceeds from royalty transactions and other (Note 4) | |||
| Acquisition of investments (Note 7) | |||
| Taxes paid on amendment of royalty interest (Note 4) | |||
| Proceeds from disposal of equity investments (Note 7) | |||
| Right of first refusal proceeds | |||
| Net cash used in investing activities | |||
| Financing activities | |||
| Proceeds from credit facility (Note 8) | |||
| Repayment of credit facility (Note 8) | |||
| Proceeds from exercise of stock options | |||
| Financing costs | |||
| Interest paid | |||
| Financing costs and interest paid | |||
| Dividends paid (Note 9e) | |||
| Proceeds from exercise of warrants and stock options (Note 9b and 9c) | |||
| Net cash used in financing activities | |||
| Effect of exchange rate changes on cash and cash equivalents | |||
| Increase in cash and cash equivalents | |||
| Cash and cash equivalents at the beginning of the year | |||
| Cash and cash equivalents |
Loading...
